Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on E-diary on a Smartphone Application and Actigraphy

Inclusion Criteria: Patients : * Subjects using a smartphone running Apple operating system (iOS 7 and above) or Android (version 2.2 and above) * Subjects agreeing to wear the actigraphy wristband at night * Subjects 18 years old or older * Subjects affiliated to French Health Insurance * Subjects treated for moderate to severe atopic dermatitis or atopic dermatitis exacerbation\* \*The stage of the atopic dermatitis will be assessed by using the Eczema Area and Severity Index (EASI), Body Surface Area (BSA) and Investigator Global Assessment (IGA). The EASI is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis. The EASI was identified as one of the best-validated outcome measures for atopic dermatitis. A moderate to severe atopic dermatitis corresponds to: * Eczema Area and Severity Index score ≥ 7.1 * Investigator Global Assessment ≥ 3 * Body Surface Area ≥ 10 Healthy volunters : * Subjects using a smartphone running iOS (iOS 7 and above) or Android (version 2.2 and above) * Subjects agreeing to wear the actigraphy wristband at night * Subjects 18 years old or older * Subjects affiliated to French Health Insurance * Subjects without a dermatology disease Non inclusion Criteria: * -Illiterate subjects * Subjects not proficient in French * Subject with a primary insomnia\* \*Insomnia, sleep apnea and hypersomnia will be evaluated with respectively 3 tests: * Insomnia Severity Index (ISI); * Berlin Sleep Apnea Scale; * Epworth Scale * Subjects treated by hypnotic drugs * Pregnant woman * Subjects under guardianship Exclusion criteria: If a participant is taking hypnotic treatments during his study participation, he will be excluded from the clinical trial.